Company intelligence / Profile preview

Orange Grove Bio

Cincinnati, Ohio, United Statesorangegrovebio.com ↗

Ownership: Private
Employees: ~34
Development stage: Preclinical

Overview

Preservation Bio’s novel additive extends refrigerated platelet storage up to 14 days with improved safety profile demonstrated in preclinical studies. Phase 1 clinical trials planned at Hoxworth Blood Center and American Red Cross focusing on platelet survival/recovery endpoints. Genexys awarded NIH SBIR grant supporting advancement of cystic fibrosis gene therapy program from preclinical toward IND-enabling studies

Therapeutic areas: OncologyPulmonologyImmunologyHematology
Modalities: Novel genetic medicinesNon-viral gene therapy platformsBiologics (immune modulation)Ex vivo biologic additivePlatelet preservation technologies
Industry: Biotech

Partnerships

University of Cincinnati College of MedicineWeizmann Institute of Science

Beyond the preview

Go deeper on Orange Grove Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orange Grove Bio.

Explore the full profile